ASCO 2022 Conference Coverage
ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy for WM: An International Collaborative Study
By
ASCO 2022 Conference Coverage
FEATURING
Jithma Abeykoon
By
ASCO 2022 Conference Coverage
FEATURING
Jithma Abeykoon
Login to view comments.
Click here to Login
Lymphoma